Acquisition from Mylan of the rights to Cystagon® (cysteamine bitartrate), indicated for the treatment of proven nephropathic cystinosis in children and adults, for certain territories, including Europe. Acquisition of Natural Point S.r.l., an Italian company active in the food supplements market whose main product is Magnesio Supremo®. A license agreement was signed with Helsinn for the exclusive rights to Ledaga® (chlormethine hydrochloride), a novel gel formulation indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma worldwide, worldwide excluding the United States, China, Hong Kong and Israel. The product has been granted Orphan Drug Designation in Europe and is approved by the European Commission. Acquisition of Tonipharm S.A.S., a French company active mainly in the self-medication market. The company’s main products are Ginkor®, OTC treatments based on ginko biloba which are very well known on the French market, and Alodont®, a line of products used for oral hygiene. Launch of Reagila® (cariprazine), a new atypical antipsychotic for the treatment of schizophrenia, in Europe.